VTX2735
Asset
Inhibitor of the NLRP3 inflammasome reducing systemic inflammation
- Stage
- Phase 2
- Modality
- Small molecule
- Target
- NLRP3
- 1
- Indication
- 1
- Trial
- 1
- Developer
Indications
1Recurrent pericarditis
Phase 2, Recruiting, NCT06836232, clinicaltrials.gov, 7 Oct 2026
In the full profile
- Targets and what it contains3
- Owner and partners1
- Trials1
- Evidence for its targets3
- Competitors10
- Aging relevance1
Every asset’s record: target, stage, trials and the evidence behind it.